Portal vein thrombosis: Etiology and clinical outcome of cirrhosis and malignancy-related non-cirrhotic, non-tumoral extrahepatic portal venous obstruction

Table 1 Clinical and laboratory findings in 118 patients with portal vein thrombosis

Parameters	Extrahepatic portal vein obstruction (n = 50)	Cirrhosis and tumor- related portal vein thrombosis (n = 68)
Male:Female	33:17	51:17
Age (yr)2	25 (9-40)	52 (23-80)
Hematemesis	36 (72%)	10 (14.7%)
Hypersplenism	30 (60%)	6 (8.8%)
Pain abdomen	18 (36%)	42 (61.8%)
Abdominal distension	8 (16%)	36 (52.9%)
Awareness of splenomegaly	6 (20%)	-
Jaundice	5 (10%)	18 (26.5%)
Cholangitis	1 (2%)	5 (7.4%)
Splenomegaly2 cm1	4 (2-14); (n = 35)	2 (2-4); (n = 7)
Hepatomegaly2 cm1	2 (1-3); (n = 8)	3 (2-6); (n = 16)
Etiology
Hepatocellular carcinoma	-	31
Cirrhosis liver	-	18
Metastases liver	-	6
Pancreatic carcinoma	-	7
Cholangio carcinoma	-	3
Carcinoma gallbladder	-	2
Duodenal carcinoid	-	1
Esophageal Varices	35 (70%)	32 (47%)
Gastric Varices	11 (22%)	3 (4.4%)
GoVI	1	2
GoV2	8	1
IGV1	2
Portal hypertensive gastropathy	8 (16%)	48 (70.4%)
Mild	6	40
Severe	2	8
Hemoglobin2 (gm/dL)	7.2 (1.7-14.7)	8.0 (6.0-11.6)
Total leucocyte count2 (103/mm3)	2.9 (1.0-6.8)	6.4 (1.36-29.71)
Platelet count2 (105/mm3)	0.49 (0.14-1.54)	1.52 (0.29-2.59)
Bilirubin2 (mg/dL)	1.0 (0.4-18.5)	1.2 (0.5-15.1)
AST2 (U/L)	38 (18-231)	79 (39-961)
ALT2 (U/L)	34 (18-254)	65 (18-1146)
SAP2 (U/L)	264 (110-2849)	348 (140-3140)
Protein/albumin2 (mg/dL)	6.8 (5-7.5)/3.8 (3-4)	6 (5.3-8)/3.3 (2-4.6)
Prothrombin time prolongation2 (seconds)	2 (1-3)	4 (2-14)
Portal biliopathy	4 (8%)
Choledocholithiasis	2
CBD stricture	2
EVL sessions2	3 (2-4)	-
Glue injection (n)	4	-
Superior mesenteric vein	11 (22%) thrombosis	6 (8.8%)
Inferior vena cava thrombosis	4 (8%)	3 (4.4%)
Splenic vein thrombosis	4 (8%)	4 (5.6%)
Deep vein thrombosis	-	1 (1.4%)
HBsAg	0	27 (39.7%)
Anti-HCV	0	3 (4.4%)

¹Centimeter below costal margin;

²Median (range).